GlassScriptPhysician profile
Brandon Baldwin
NPI 1891422929
$2,826.47
in general payments reported to CMS, 2019-2025
31 companies · $2,368 in 2025
The $2,368 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $459 · 2025: $2,368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,826.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,826.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $683.61 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $387.19 | 2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $206.03 | 2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.07 | 2024-2025 | Jardiance |
| Pfizer INC. | $154.34 | 2025 | |
| Madrigal Pharmaceuticals | $119.82 | 2024-2025 | Rezdiffra, Resmetirom |
| Aimmune Therapeutics, INC. | $93.36 | 2024-2025 | Zenpep |
| Axsome Therapeutics, INC. | $90.14 | 2024-2025 | Auvelity |
| Corcept Therapeutics | $90.04 | 2025 | Korlym |
| Amgen INC. | $81.22 | 2024-2025 | Evenity, Prolia |
| Glaxosmithkline, LLC. | $72.94 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $66.76 | 2024-2025 | Mounjaro, Zepbound |
| Vertex Pharmaceuticals Incorporated | $60.80 | 2025 | |
| Daiichi Sankyo INC. | $58.90 | 2025 | Injectafer |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $58.13 | 2025 | Caplyta |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $53.10 | 2024-2025 | Rexulti |
| Viatris Specialty LLC | $46.16 | 2025 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $42.88 | 2024-2025 | |
| Vanda Pharmaceuticals INC. | $40.21 | 2024-2025 | Ponvory, Fanapt, Hetlioz |
| Tandem Diabetes Care, INC. | $34.87 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Mylan Specialty L.P. | $30.95 | 2024 | Yupelri |
| Janssen Pharmaceuticals, INC | $26.88 | 2024 | Spravato |
| C2n Diagnostics, LLC | $24.35 | 2025 | Precivityad2 |
| Lundbeck LLC | $21.94 | 2025 | Rexulti |
| Exact Sciences Corporation | $21.12 | 2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.10 | 2025 | Xifaxan |
| Xeris Pharmaceuticals, INC. | $18.82 | 2024 | Gvoke Hypopen |
| Verity Pharmaceuticals INC. | $15.40 | 2025 | Tlando |
| Phathom Pharmaceuticals, INC. | $15.10 | 2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $14.07 | 2024 | Trintellix |
| Idorsia Pharmaceuticals US INC | $13.17 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Baldwin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.